4 Biotechnology Stocks to Sell Now

Advertisement

This week, the overall grades of four biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Trius Therapeutics, Inc.’s (TSRX) rating falls to a D (“sell”) this week, down from C (“hold”) the week prior. Trius Therapeutics is a biopharmaceutical company. In Portfolio Grader’s specific subcategories of Earnings Growth, Earnings Momentum, Equity, Cash Flow and Sales Growth, TSRX also gets F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

Protalix Biotherapeutics, Inc.’s (PLX) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Protalix BioTherapeutics is a biotechnology company that has developed plant cell culture technology and a bioreactor system. The stock also rates an F in Cash Flow. For more information, get Portfolio Grader’s complete analysis of PLX stock.

This is a rough week for Synta Pharmaceuticals (SNTA). The company’s rating falls to F from the previous week’s D. Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The stock gets F’s in Equity and Cash Flow. As of Jan. 7, 2015, 10.8% of outstanding Synta Pharmaceuticals shares were held short. To get an in-depth look at SNTA, get Portfolio Grader’s complete analysis of SNTA stock.

CytRx Corporation (CYTR) earns an F this week, moving down from last week’s grade of D. CytRx is a biopharmaceutical research and development company that specializes in oncology. The stock gets F’s in Equity and Cash Flow. As of Jan. 7, 2015, 22.3% of outstanding CytRx Corporation shares were held short. For more information, get Portfolio Grader’s complete analysis of CYTR stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/01/4-biotechnology-stocks-to-sell-now-tsrx-plx-snta/.

©2024 InvestorPlace Media, LLC